In plain words

In most of the small, short trials here, grape seed extract lowered blood signs of oxidative stress or raised the body's own antioxidants. Two of the seven trials found no difference from placebo on what they measured.

The short answer

Five of seven randomized trials point toward lower oxidative stress: Vigna (24 smokers, 300 mg daily, 4 weeks), Kar (32 people with diabetes, 600 mg daily, 4 weeks), Razavi (52 adults, 200 mg daily, 8 weeks), Taghizadeh (40 athletes, 300 mg twice daily, 8 weeks) and Nuttall (20 volunteers, two capsules containing 300 mg daily, 5 days). Two found no difference from placebo: Preuss (40 adults, 100 mg twice daily, 2 months) and Mellen (50 people, 1,300 mg muscadine seed daily, 4 weeks). Certainty is low because the trials are small and short, and they measured different markers.

Where the evidence sits

Markers improved

■ Randomized trial, Vigna et al., 2003 · 24 people · 4 weeks
■ Randomized trial, Kar et al., 2009 · 32 people · 4 weeks
■ Randomized trial, Razavi et al., 2013 · 52 people · 8 weeks
■ Randomized trial, Taghizadeh, 2016 · 40 people · eight weeks · antioxidant capacity no different
■ Randomized trial, Nuttall et al., 1998 · 20 people · 5 days
◪ Pooled analysis, Foshati, 2021 · may overlap studies counted here · antioxidant capacity rise marginal

No difference

■ Randomized trial, Preuss et al., 2000 · 40 people · two months
◪ Pooled analysis, Sarkhosh-Khorasani, 2021 · may overlap studies counted here · antioxidant capacity rose
□ Randomized trial reported by Mellen, 2010 · Mellen muscadine seed crossover trial · no new data

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight7777 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Vigna et al., 2003Lower TBARSRandomized crossover24300 mg/day, 4 weeksNot in ledger
Kar et al., 2009Glutathione roseRandomized32600 mg/day, 4 weeksNot in ledger
Razavi et al., 2013Lower oxidized LDLRandomized crossover52200 mg/day, 8 weeksNot in ledger
Taghizadeh et al., 2016Glutathione roseRandomized40300 mg twice daily, 8 weeksNot in ledger
Nuttall et al., 1998Antioxidant capacity roseRandomized crossover20Two capsules containing 300 mg daily, 5 daysNot in ledger
Preuss et al., 2000No differenceRandomized40100 mg twice daily, 2 monthsNot in ledger
Mellen et al., 2010Not significantRecord describing a randomized trial501,300 mg daily, 4 weeksNot in ledger
Vigna et al., 2003

Lower TBARS

Design
Randomized crossover
People
24
Dose and length
300 mg/day, 4 weeks
Funding
Not in ledger
Kar et al., 2009

Glutathione rose

Design
Randomized
People
32
Dose and length
600 mg/day, 4 weeks
Funding
Not in ledger
Razavi et al., 2013

Lower oxidized LDL

Design
Randomized crossover
People
52
Dose and length
200 mg/day, 8 weeks
Funding
Not in ledger
Taghizadeh et al., 2016

Glutathione rose

Design
Randomized
People
40
Dose and length
300 mg twice daily, 8 weeks
Funding
Not in ledger
Nuttall et al., 1998

Antioxidant capacity rose

Design
Randomized crossover
People
20
Dose and length
Two capsules containing 300 mg daily, 5 days
Funding
Not in ledger
Preuss et al., 2000

No difference

Design
Randomized
People
40
Dose and length
100 mg twice daily, 2 months
Funding
Not in ledger
Mellen et al., 2010

Not significant

Design
Record describing a randomized trial
People
50
Dose and length
1,300 mg daily, 4 weeks
Funding
Not in ledger

Which trials found a change?

Vigna and colleagues (2003) gave 24 male heavy smokers 300 mg a day or placebo for 4 weeks; LP is their extract group:

thiobarbituric acid reactive substances (TBARS) concentration was significantly reduced in subjects taking LP

Kar and colleagues (2009) found whole blood glutathione rose in 32 people with type 2 diabetes on 600 mg a day for 4 weeks, but not on placebo. Razavi and colleagues (2013) found lower oxidized LDL in 52 adults with mildly raised blood fats on 200 mg a day for 8 weeks. Taghizadeh and colleagues (2016) found glutathione higher and malondialdehyde lower than placebo in 40 volleyball players on 300 mg twice a day for 8 weeks, with total antioxidant capacity unchanged. Nuttall and colleagues (1998) found total antioxidant capacity rose in 20 young volunteers taking two capsules containing 300 mg daily for 5 days.

Which trials found no difference?

Preuss and colleagues (2000) compared groups of 40 adults taking 100 mg twice a day or not for two months:

no statistically significant differences were seen in the levels of autoantibodies to oxidized LDL (Ox-LDL)

A Europe PMC record describes Mellen and colleagues' (2010) randomized trial of 1,300 mg muscadine grape seed daily for 4 weeks in 50 people with or at risk for cardiovascular disease; oxidation markers did not change significantly.

What do the pooled analyses add?

A meta-analysis by Foshati and colleagues (2021) found lower malondialdehyde and oxidized LDL and a marginal rise in total antioxidant capacity, a pooled estimate that may include the trials above.

Sarkhosh-Khorasani and colleagues (2021) combined several grape products in a pooled estimate that may include the trials above, and found total antioxidant capacity rose, but:

it had no significant impact on other oxidative stress biomarkers.

Why the sources disagree

Each trial measured a different marker: TBARS, glutathione, oxidized LDL, antibodies to oxidized LDL or total antioxidant capacity. Total antioxidant capacity splits most: it rose in Nuttall's trial and in Sarkhosh-Khorasani's pooled analysis, not in Taghizadeh's trial, and only marginally in Foshati's; both pooled estimates may include the trials above. Mellen's trial used muscadine seed, and Sarkhosh-Khorasani pooled several grape products. People ranged from young volunteers and athletes to smokers and people with diabetes. The ledger has no funding for any of these studies.

What would settle it

An independent, pre-registered trial randomizing 200 adults to 300 mg of grape seed extract a day or placebo for 12 weeks, with plasma malondialdehyde as the single primary outcome and glutathione, oxidized LDL and total antioxidant capacity as secondary outcomes, all compared against placebo. A matching result from a second research group would raise certainty from low to moderate.

How this page was made

The 9 sources are seven randomized trials and two meta-analyses, pooled estimates that may include the trials above, from a literature search of PubMed and Europe PMC records; animal studies from the search were left out. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

Changelog: 4 Oct 2026, first version, 9 sources.